Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in ChileTerapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile

Simple item page
dc.article.number1364000
dc.contributor.authorCandia R.
dc.contributor.authorVargas J.I.
dc.contributor.authorMansilla R.
dc.contributor.authorArenas A.
dc.contributor.authorChahuan J.
dc.contributor.authorEspino A.
dc.contributor.authorPizarro M.
dc.contributor.authorRiquelme A.
dc.contributor.authorReyes D.
dc.contributor.authorOrtiz J.
dc.contributor.authorFuentes-Lopez E.
dc.contributor.authorRiquelme A.
dc.contributor.authorBudnik S.
dc.contributor.authorGandara V.
dc.contributor.authorGallardo A.
dc.contributor.authorSeydewitz M.F.
dc.contributor.authorRollan A.
dc.contributor.authorRollan M.P.
dc.contributor.authorGodoy J.
dc.contributor.authorMansilla R.
dc.contributor.authorVargas J.I.
dc.contributor.authorArenas A.
dc.date.accessioned2024-10-15T07:00:15Z
dc.date.available2024-10-15T07:00:15Z
dc.date.issued2021
dc.description.abstract© 2021 Elsevier España, S.L.U.Introduction: Helicobacter pylori infection affects approximately 70% of the Chilean population. It is a public health problem whose eradication treatment is part of the explicit health guarantees in Chile. Objectives: Characterize the most widely used H. pylori first-line eradication therapies in our environment and evaluate their efficacy. Methods: A retrospective observational study was carried out where, in patients with certified H. pylori infection, the eradication therapy indicated by the treating physician, its efficacy, adherence and adverse effects, in addition to the eradication certification method used, were evaluated. Results: 242 patients and 4 main therapies were analyzed: standard triple therapy, dual therapy, concomitant therapy, and bismuth quadruple therapy. Eradication rates of 81.9% (95% CI 74.44–87.63), 88.5% (95% CI 73.13–95.67), 93.7% (95% CI 78.07–98.44) and 97.6% (95% CI 84.81–99.67) were observed respectively, with concomitant therapy (RR: 1.14; 95% CI 1.01–1.29; p = .028) and quadruple therapy with bismuth (RR: 1.19; 95% CI 1.09–1.31; p < .001) being significantly more effective than standard triple therapy. Regarding the rate of reported adverse effects, it was 58.5% (95% CI 50.66–65.92), 35.4% (95% CI 24.6–48.11), 22.9% (95% CI 81–37.14) and 63.4% (95% CI 47.8–76.64), having the dual and concomitant therapy significantly fewer adverse effects compared with standard therapy. Conclusions: Quadruple therapies are superior to standard triple therapy and should be considered as first-line treatment in Chile. Dual therapy is promising. More studies will be required to determine which therapies are most cost-effective.
dc.description.funderAgencia Nacional de Investigaci?n y Desarrollo
dc.description.funderAgencia Nacional de Investigación y Desarrollo
dc.description.funderCRIP
dc.description.funderFLUOMICS Consortium
dc.description.funderNIH
dc.description.funderNIAID
dc.description.funderFONDECYT
dc.format.extent559 páginas
dc.fuente.origenScopus
dc.identifier.doi10.1016/j.gastrohep.2021.11.010
dc.identifier.eissn15789519
dc.identifier.issn15789519 02105705
dc.identifier.pubmedid35077722
dc.identifier.scopusidSCOPUS_ID:85121916701
dc.identifier.urihttps://doi.org/10.1016/j.gastrohep.2021.11.010
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/88224
dc.identifier.wosidWOS:000844073200003
dc.information.autorucFacultad de Medicina; Fuentes Lopez, Eduardo; S/I; 1013849
dc.issue.numero6
dc.language.isoen
dc.nota.accesoSin adjunto
dc.pagina.final20
dc.pagina.inicio14
dc.relation.ispartofGastroenterologia y Hepatologia
dc.revistaGastroenterologia y Hepatologia
dc.rightsacceso cerrado
dc.subjectAntibiotic resistance
dc.subjectEradication rates
dc.subjectHelicobacter pylori
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleQuadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in ChileTerapias cuádruples son superiores a terapia triple estándar en primera línea de erradicación de Helicobacter pylori en Chile
dc.typeartículo
dc.volumen12
sipa.codpersvinculados1013849
sipa.indexScopus
sipa.trazabilidadCarga WOS-SCOPUS;15-10-2024
Files
Collections
Artículos de revistas